In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?

Executive Summary

In early January, Genzyme nabbed one of the highest-value specialist cholesterol-busting drugs around: Phase III mipomersen, from Isis Pharmaceuticals. But given the ENHANCE-triggered questions around the value of ever-lower LDL, it's reasonable to ask whether mipomersen has a somewhat less rosy prospect in the few weeks since the deal was signed.
Advertisement

Related Content

GSK/Actelion: Phase III Value Is in the Eye of the Beholder
Best of the Blog: IN VIVO, May 2008
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Isis: Pondering Platform Power
Change of Control: Why Getting it Right Matters Even More
Pharma's New Follow-On Strategy
Almirall: Adapting Primary-Care-focused R&D to a Specialist World
Genzyme: Why Diversification is Starting to Look Smart
Genzyme: Why Diversification is Starting to Look Smart
Exelixis/GSK: Using Project Financing to Accelerate R&D

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel